摘要
目的探讨贝伐单抗联合培美曲塞治疗晚期非小细胞肺癌的疗效以及不良反应。方法收集200例晚期非小细胞肺癌患者作为研究对象，将200例患者随机分为对照组和治疗组，每组100例。对照组采用顺铂＋培美曲塞化疗，治疗纽在顺铂＋培美曲塞的基础上加贝伐单抗，比较2组用药后的疗效及不良反应。结果治疗组患者的ORR（CR＋PR）和DCR（CR＋PR＋SD）分别为43％、85％，相比于对照组ORR和DCR的20％、69％，差畀明显，具有统计学意义（P〈0．05）。对照组和治疗组的化疗过程中的不良反应如呕吐、血小板减少、中性粒细胞减少、肝肾功能异常无论在发生率还是在0～Ⅳ级分级上都没有明显差异，不具统计学意义（P〉0．05）。治疗组的血管内皮细胞生长因子AmRNA含量为（70．6±12．3）pg·mL^-1、血管内皮细胞生长因子BmRNA含量为（67．4±11．3）pg·mL^-1、血管内皮细胞生长因子CmRNA含量为（63．9±11．7）pg·mL^-1，都明显低于对照组，差异具有统计学意义（P〈0．05）。结论贝伐单抗联合培美曲塞及顺铂对晚期非小细胞肺癌的临床治疗效果理想，患者耐受性好，无明显的不良反应，且贝伐单抗对血管内皮细胞生长因子具有抑制作用，目前可以作为1种较为理想的晚期非小细胞肺癌的治疗方案。
Objective To explore the efficacy and adverse reactions of bevacizumab combined with pemetrexed for advanced non-small cell lung cancer. Methods 200 cases of advanced non-small cell lung cancer were randomly divided into the treatment group and the control group, 100 cases in each. The control group received cisplatin ＋ pemetrexed, the treatment group received cisplatin ＋ pemetrexed and bevacizumab. Curative efficacy and adverse reactions of the 2 groups were compared after treatment. Results ORR （ CR ＋ PR） and DCR （ CR ＋ PR ＋ SD ） in the treatment group were 43% , 85 % , and ORR （ CR ＋ PR） and DCR （ CR ＋ PR ＋ SD） in the control group were 20% ,69% , there had statistical difference （ P 〈 0.05 ）. There had no statistical difference in the incidence of adverse reactions such as vomiting, thrombocytopenia, neutropenia, liver and kidney abnormal function and 0 - Ⅳ grade between the 2 groups（P 〉 0.05）. Compared the treatment group of vascular endothelial cell growth factor mRNA levels with the control group, vascular endothelial growth factor A was （70.6 ±12.3 ） pg·mL^-1, vascular endothelial growth factor B was （67.4 ± 11.3 ）pg·mL^-1, vascular endothelial growth factor C was （ 63.9 ± 11.7 ） pg·mL^-1 mRNA levels, which were significantly lower than those of the control group, there had statistical difference （ P 〈 0.05 ）. Conclusion Bevacizumab combined with pemetrexed and eisplatin for advanced non-small cell lung cancer is effective with good tolerance and no obvious adverse reactions, and bevacizumab has inhibitive effect on vascular endothelial cell growth factor,it can be ideal method for advanced non-small cell lung cancer.
出处
《实用癌症杂志》
2016年第3期373-376,共4页
The Practical Journal of Cancer
关键词
贝伐单抗
培美曲塞
非小细胞肺癌
临床应用
Bevacizumab
Pemetrexed
Non-small cell lung cancer
Clinical application
